-
Mashup Score: 1
Schafer Boeder, MD describes the potential role and safety of adjunctive therapy, including SGLT2 inhibitors and GLP-1 agonists, for patients with T1D.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
Schafer Boeder, MD describes the potential role and safety of adjunctive therapy, including SGLT2 inhibitors and GLP-1 agonists, for patients with T1D.
At #WCIRDC2024, Schafer Boeder, MD, University of California, San Diego, describes the potential role and safety of adjunctive therapy, including SGLT2 inhibitors and GLP-1 agonists, for patients with type 1 diabetes (T1D). 🔗https://t.co/rtucqllMhq #22WCIRDC https://t.co/bGRAGFxt2b